Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 3
2015 15
2016 16
2017 11
2018 16
2019 27
2020 27
2021 40
2022 29
2023 51
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
Hyperkalemia in chronic kidney disease.
Watanabe R. Watanabe R. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s31-s36. doi: 10.1590/1806-9282.66.S1.31. Rev Assoc Med Bras (1992). 2020. PMID: 31939533 Free article. Review.
Clinical Management of Hyperkalemia.
Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, Hain DJ, Lerma E, Onuigbo M, Rastogi A, Roger SD, Spinowitz BS, Weir MR. Palmer BF, et al. Mayo Clin Proc. 2021 Mar;96(3):744-762. doi: 10.1016/j.mayocp.2020.06.014. Epub 2020 Nov 5. Mayo Clin Proc. 2021. PMID: 33160639 Free article. Review.
Recent clinical studies suggest that the newer K(+) binders (patiromer sorbitex calcium and sodium zirconium cyclosilicate) may facilitate optimization of RAASi therapy. ...
Recent clinical studies suggest that the newer K(+) binders (patiromer sorbitex calcium and sodium zirconium cyclosilicate …
Sodium zirconium cyclosilicate in hyperkalemia.
Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Packham DK, et al. N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21. N Engl J Med. 2015. PMID: 25415807 Free article. Clinical Trial.
BACKGROUND: Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associated with increased mortality among patients with heart failure, chronic kidney disease, or diabetes. We investigated whether sodium zirconium cyclosilicate (ZS-9), a novel sele …
BACKGROUND: Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associated with increased mortality among patients with heart fa …
Potassium Disorders: Hypokalemia and Hyperkalemia.
Kim MJ, Valerio C, Knobloch GK. Kim MJ, et al. Am Fam Physician. 2023 Jan;107(1):59-70. Am Fam Physician. 2023. PMID: 36689973
Dialysis may be considered in the presence of end-stage renal disease, severe renal impairment, or ongoing potassium release. Patiromer and sodium zirconium cyclosilicate are newer potassium binders and may be used in chronic or acute hyperkalemia. ...
Dialysis may be considered in the presence of end-stage renal disease, severe renal impairment, or ongoing potassium release. Patiromer and …
Hyperkalemia: Prevalence, Predictors and Emerging Treatments.
Larivée NL, Michaud JB, More KM, Wilson JA, Tennankore KK. Larivée NL, et al. Cardiol Ther. 2023 Mar;12(1):35-63. doi: 10.1007/s40119-022-00289-z. Epub 2022 Dec 12. Cardiol Ther. 2023. PMID: 36503972 Free PMC article. Review.
Acute Management of Hyperkalemia.
Liu M, Rafique Z. Liu M, et al. Curr Heart Fail Rep. 2019 Jun;16(3):67-74. doi: 10.1007/s11897-019-00425-2. Curr Heart Fail Rep. 2019. PMID: 30972536 Review.
RECENT FINDINGS: Two new oral potassium-binding agents, patiromer and sodium zirconium cyclosilicate, show promise in the management of hyperkalemia. ...
RECENT FINDINGS: Two new oral potassium-binding agents, patiromer and sodium zirconium cyclosilicate, show promise in t …
Controversies in Management of Hyperkalemia.
Long B, Warix JR, Koyfman A. Long B, et al. J Emerg Med. 2018 Aug;55(2):192-205. doi: 10.1016/j.jemermed.2018.04.004. Epub 2018 May 3. J Emerg Med. 2018. PMID: 29731287 Review.
New medications to promote gastrointestinal K+ excretion, which include patiromer and sodium zirconium cyclosilicate, hold promise. CONCLUSIONS: Hyperkalemia can be deadly, and treatment requires specific measures including membrane stabilization, cellular sh …
New medications to promote gastrointestinal K+ excretion, which include patiromer and sodium zirconium cyclosilicate, h …
Sodium Zirconium Cyclosilicate.
[No authors listed] [No authors listed] 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30694621 Free Books & Documents. Review.
Because sodium zirconium cyclosilicate is not orally absorbed it is unlikely to reach the breastmilk or adversely affect the breastfed infant. ...
Because sodium zirconium cyclosilicate is not orally absorbed it is unlikely to reach the breastmilk or adversely affec …
A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia.
Cañas AE, Troutt HR, Jiang L, Tonthat S, Darwish O, Ferrey A, Lotfipour S, Kalantar-Zadeh K, Hanna R, Lau WL. Cañas AE, et al. BMC Nephrol. 2023 Apr 5;24(1):89. doi: 10.1186/s12882-023-03145-x. BMC Nephrol. 2023. PMID: 37016309 Free PMC article. Clinical Trial.
METHODS: Emergency room and hospitalized patients with a blood potassium level 5.5 mEq/L are randomized to one of four study groups: potassium binder drug (sodium polystyrene sulfonate, patiromer, or sodium zirconium cyclosilicate) or nonspecific laxative (po …
METHODS: Emergency room and hospitalized patients with a blood potassium level 5.5 mEq/L are randomized to one of four study groups: potassi …
229 results